Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 3/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27660942 | 0.92 | NQO2 (0.40) | NQO2RXFP1POLBLMNABRD9 | |
| SCHEMBL6802648 | 0.88 | LMNA (0.45) | RXFP1POLBLMNABRD9NPSR1 | |
| SCHEMBL28736190 | 0.86 | NR1H4 (0.45) | NQO2RXFP1POLBLMNABRD9 | |
| SCHEMBL27433809 | 0.84 | NQO2 (0.39) | NQO2RXFP1POLBLMNABRD9 | |
| SCHEMBL8661032 | 0.81 | NQO2 (0.38) | NQO2RXFP1POLBLMNABRD9 | |
| SCHEMBL6784474 | 0.80 | MTNR1A (0.44) | NQO2POLBLMNA | |
| SCHEMBL27309736 | 0.80 | CTSS (0.42) | NQO2RXFP1POLBLMNAHSP90AA1 | |
| SCHEMBL27983901 | 0.80 | POLB (0.40) | NQO2RXFP1POLBLMNABRD9 | |
| SCHEMBL6502501 | 0.80 | LMNA (0.43) | RXFP1POLBLMNABRD9BRD4 | |
| SCHEMBL8660694 | 0.80 | NPSR1 (0.48) | RXFP1POLBLMNABRD9NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169843-A1 | NOVEL ANTITUMORAL USE OF CABAZITAXEL | SANOFI MATURE IP (FR) | 2021-06-10 | — | — | US | disclosed |
| CN-101959501-B | stable single-liquid pharmaceutical composition containing docetaxel | DONG A PHARM CO LTD | 2012-08-29 | — | — | CN | disclosed |
| CN-101959501-A | Stable single-liquid pharmaceutical composition containing docetaxel | DONG A PHARM CO LTD | 2011-01-26 | — | — | CN | disclosed |
| US-6593482-B2 | (2R,3S)-3-benzoyl-2-hydroxy-3-phenylpropionate of 4,10-beta-diacetoxy-2 alpha-benzoyloxy-5 beta ,20-epoxy-1,13-alpha-dihydroxy-7-beta-methylthiomethyloxy-9-oxo-tax-11-ene from baccatin and beta-lactam | AVENTIS PHARMA S.A. (FR) | 2003-07-15 | — | — | US | disclosed |
| US-20020087013-A1 | Methods for preparing new taxoids and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2002-07-04 | — | — | US | disclosed |
| US-20020010348-A1 | Methods for preparing new taxoids and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6232477-B1 | SILYLATING A BACCATIN; ACETYLATION; DEBLOCKING | AVENTIS PHARMA S.A. (FR) | 2001-05-15 | — | — | US | disclosed |
| US-6040466-A | Taxoids, their preparation and pharmaceutical compositions containing them | RHONE POULENC RORER SA (FR) | 2000-03-21 | — | — | US | disclosed |
| US-5760251-A | Taxol process and compounds | SEPRACOR, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1997007110-A1 | PROCESS FOR PRODUCING TAXOL DERIVATIVES AND INTERMEDIATES THEREFOR | SEPRACOR, INC. (US) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010348-A1 | Methods for preparing new taxoids and pharmaceutical compositions containing them | TOP1, TMSB4X, TUBB1 | NQO2 766/4885RXFP1 4136/4885POLB 1794/4885 |
| US-20020087013-A1 | Methods for preparing new taxoids and pharmaceutical compositions containing them | TOP1, TMSB4X, TUBB1 | NQO2 766/4885RXFP1 4136/4885POLB 1794/4885 |
| US-20210169843-A1 | NOVEL ANTITUMORAL USE OF CABAZITAXEL | KLK3, NR5A1, HSD17B7 | NQO2 2381/4885RXFP1 4241/4885POLB 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.